# MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function

> **NCT03606538** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Resilient Pharmaceuticals** · enrollment: 16 (estimated)

## Conditions studied

- Pharmacokinetics
- Hepatic Impairment

## Interventions

- **DRUG:** Midomafetamine HCl

## Key facts

- **NCT ID:** NCT03606538
- **Lead sponsor:** Resilient Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-29
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2024-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03606538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03606538, "MDMA in Subjects With Moderate Hepatic Impairment and Subjects With Normal Hepatic Function". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03606538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*